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Abstract 
 
Chronic pain is an unmet clinical problem with vast individual, societal and economic impact. 
Pathologic activity of the peripheral somatosensory afferents is one of the major drivers of chronic 
pain. This overexcitable state of somatosensory neurons is, in part, produced by the dysregulation of 
genes controlling neuronal excitability. Despite intense research, a unifying theory behind neuropathic 
remodelling is lacking. Here we show that transcriptional suppressor, repressor element 1-silencing 
transcription factor (REST, NRSF), is necessary and sufficient for the development of hyperalgesic 
state following chronic nerve injury or inflammation. Viral overexpression of REST in mouse DRG 
induced prominent mechanical and thermal hyperalgesia in vivo. Sensory neuron specific, inducible 
Rest knock-out prevented the development of such hyperalgesic state in three different chronic pain 
models. Genetic deletion of Rest reverted injury-induced hyperalgesia. Moreover, viral overexpression 
of REST in the same neurons in which its gene has been genetically deleted restored neuropathic 
hyperalgesia. Finally, sensory neuron specific Rest knockout prevented injury-induced downregulation 
of REST target genes in DRG neurons. This work identified REST as a major regulator of peripheral 
somatosensory neuron remodelling leading to chronic pain. The findings might help to develop a novel 
therapeutic approaches to combat chronic pain. 
 
 
Keywords: chronic pain; epigenetics; K+ channel; Repressor element 1-silencing transcription factor; 
REST; NRSF 
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Introduction 
Chronic pain constitutes an enormous ongoing health problem, yet, despite centuries of research 
and investment, the new treatments are slow coming and opioids are still a ‘gold standard’. 
Pathological changes within both peripheral and central nociceptive pathways contribute to the 
development and maintenance of chronic pain [10]. One of the common peripheral causes of chronic 
pain is a pathological activity of a subset of peripheral nerves (nociceptors) which are normally silent 
and only become active in response to potentially damaging noxious stimuli.  
Nerve injury triggers prominent morphological and epigenetic changes within afferent nerves. 
Mechanisms contributing to such remodelling include local inflammation [29], sympathetic sprouting 
[7; 24] and a large-scale changes in gene expression in nociceptors, driving them into an over-excitable 
state [3; 28; 41]. Control of gene expression is orchestrated by transcription factors that chemically 
modify DNA or histones (reviewed in [28]). One of such transcription factors upregulated in sensory 
neurons after nerve injury [30; 38; 39; 43; 44] and contributing to chronic pain development is the 
repressor element 1-silencing transcription factor REST (also known as neuron-restrictive silencing 
factor, NRSF) [38; 39; 43; 44]. REST is a zinc-finger transcription factor mediating both short- and 
long-term transcriptional suppression of target genes containing RE1 binding sites within their 
promotor regions. REST forms a large complex with other enzymes and regulators, including CoREST, 
LSD1, BHC80, and BRAF35 [26-28]; it also recruits additional enzymes, including MeCP2, histone 
deacetylases HDAC1/2, and the histone methyltransferase G9a. Acting together, these elements of the 
complex suppress gene expression by removing active histone marks, such as H3K4 methylation or 
various histone acetylations and adding repressive histone marks such as H3K9 methylation [1; 2; 27; 
28]. 
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The main physiological role of REST was initially considered to be in a suppression of neuronal 
genes in non-neuronal cells [6; 31]. While now REST is thought to play some important roles in several 
neural disorders and brain ageing, the expression of REST in healthy neurons is generally low ([35; 
40]). However, expression of REST in peripheral somatosensory neurons was shown to be elevated in 
neuropatic [30; 38; 39; 43] and bone cancer pain [44] models. These studies also revealed that the 
expression of some of REST target genes, including Kcnd3, Kcnq2, Scn10a and Oprm1 (coding for 
Kv4.3, Kv7.2, Nav1.8 ion channels and µ-opioid receptors, respectively) was concurrently repressed. 
These changes were further correlated with the development of hyperalgesia, C fiber overexcitability 
and a reduction in the efficacy of opioid analgesia [30; 38; 39; 44]. Intrathecal injection of Rest 
antisense oligonucleotides or siRNA alleviated some of these transcriptional and behavioural changes 
[38; 43; 44] suggesting that REST is an important driver of these pathological responses.  
While a proalgesic role of REST in peripheral somatosensory system is being increasingly 
recognised, the overall contribution of REST to the development of chronic pain remains unclear. In 
this study we used in vivo viral gene delivery and sensory neuron restricted, inducible Rest knockout to 
demonstrate that REST is necessary and sufficient for the development of chronic pain. 
 
Methods. 
Animals. Animal experiments performed in Hebei Medical University were in accordance to the 
Animal Care and Ethical Committee of Hebei Medical University, (Shijiazhuang, China) under the 
International Association for the Study of Pain (IASP) guidelines. Animal experiments performed in 
the University of Leeds were in accord with the regulations of the Research Ethics Committee of the 
Faculty of Biological Sciences at the University of Leeds and under the provisions of the UK Animals 
(Scientific Procedures) Act 1986. For the generation of RestloxP/loxP/AvCreER-T2 mouse line, Rest 
loxP/loxP
 mice [34] were crossed with the AvCreER-T2 mice [20], kindly provided by Prof John Wood 
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(UCL). To induce Cre recombinase activity five daily i.p. injections of tamoxifen (2 mg in 0.2 ml of 
sunflower oil) were given to the mice. In later experiments the amount of tamoxifen injections was 
reduced to four as genotyping confirmed that it was sufficient to induce the knockout. In the 
experiments with knockout mice both male and female animals were used. 
Viral gene delivery to DRG. AAV2/9-CMV-REST, AAV2/9-CMV-NULL, AAV2/9-DIO-REST 
and AAV2/9-DIO-NULL virions were produced by Hanbio Biotechnology Co. Ltd. AAV2/9 virion 
injections into the right-side L4 DRG of C57BL/6 male mice or transgenic mice of either sex were 
performed as previously described [14]. Briefly, in deeply anesthetised mice (sodium pentobarbital, 80-
100 mg/kg; i.p.) L4 DRGs were exposed by removal of booth spinous and transverse processes of the 
vertebra bone. The microinjector (Hamilton Company) was inserted into the ganglion to a depth of 500 
µm from the exposed surface. The virion solution (1.1 - 1.2x1012 vg/ml; 5 µl) was injected slowly and 
the needle was removed 2 min after the injection was complete. The muscles overlying the spinal cord 
were loosely sutured together and the wound was closed. Thermal and mechanical sensitivity tests were 
performed before the injection and at a weekly interval after the injection. At 28 days post-injection 
animals were sacrificed, L4 DRGs extracted and tested for expression of Myc-tagged REST using 
immunohistochemistry. Animals developing signs of distress were sacrificed.  
Chronic pain models. To induce chronic inflammatory pain a complete Freund’s adjuvant (CFA, 
20 µl) was injected into the plantar surface of the right hind paw of the mice as described [14]. Partial 
sciatic nerve ligation (PSNL) was performed as described [30]. Briefly, mice were anesthetised with 
2% v/v isoflurane; the left sciatic nerve was exposed at mid-thigh level and cleared of surrounding 
connective tissues. A 6-0 Prolene suture (Ethicon Ltd. Edinburgh, UK) was inserted into the nerve with 
a 3/8 curved, reversed-cutting needle, and tightly ligated so that the dorsal third/half of the nerve was 
held within the ligature. A small cut was made approximately 5 mm below the ligature. The wound was 
then closed with sutures. In sham-operated mice, the left sciatic nerve was exposed but untouched.  
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The spared nerve injury (SNI) was performed following the procedure described previously [8]. 
Briefly, under deep anaesthesia (sodium pentobarbital, 80-100 mg/kg, i.p.) three distal branches of the 
right sciatic nerve were exposed carefully without damaging the muscle bundles. The common 
peroneal and the tibial nerves were explored and tightly ligated with 5–0 silk and transected distal to 
the ligation, removing a 2-4 mm length of each nerve. Great care was taken to avoid any contact with 
or stretching of the intact sural nerve. The wound was closed with sutures.  
Behavioral tests. In all tests animals were habituated to the testing environment for at least 3 h 
before testing. Mechanical withdrawal threshold was measured by a set of von Frey filaments 
(Stoelting Co, Chicago, IL, USA) with a calibrated range of bending force. Each animal was placed 
into a plastic cage with a wire mesh bottom. A single filament was applied perpendicularly to the 
plantar surface of hind paw. A response was considered as positive when the animal withdrew sharply 
its paw; the same stimulus was applied for five times with an interval of 5s. In the withdrawal threshold 
measurements, the threshold was recorded when three clear withdrawal responses out of five 
applications were observed with a given filament. For the 50% withdrawal threshold method, the 50% 
threshold was determined using the up and down method according the protocol described in [5]. The 
50% threshold value was determined according to the following equation: 50% withdrawal threshold = 
(10[Xf+kδ])/10,000; where Xf is a value (in log units) of the final von Frey filament used; k is a tabular 
value for the pattern of positive/negative responses; and δ is a mean difference (in log units) between 
stimuli [5]. 
Thermal withdrawal latency was tested by a radiant heat lamp source (PL-200, Taimeng Co, 
Chengdu, China). The intensity of the radiant heat source was maintained at ~25%. Animals were 
placed individually into Plexiglas cubicles with a transparent glass surface. The light beam from radiant 
heat lamp, located below the glass, was directed at the plantar surface of hindpaw. The time was 
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recorded from the onset of radiant heat stimulation to withdrawal of the hindpaw. Three trials with an 
interval of 5 min were made for each paw/animal, and scores from three trials were averaged. 
Cold sensitivity was assessed in the cold plate test using the cold plate apparatus (hot/cold plate, 
Bioseb, France). Mice were placed on a 1  cold plate, and the latency to the first brisk hind paw lift or 
flicking/licking of the hind paw or jumping was measured, with a cut-off time of 120 s. Number of 
flinches/jumps within 120 s was also measured.  
Whenever practical, behavioural experiments were performed by an experimenter blinded to 
genetic background of animals or treatment schedule. 
Immunohistochemistry. L4 DRGs were dissected, post-fixed in 4% paraformaldehyde at 4 °C for 
2 h, and cryoprotected in 20% sucrose in PBS at 4 °C overnight. Before staining, 10 m sections were 
post-fixed with 4% paraformaldehyde in PBS for 10 min. After blocking in 10% goat serum and 0.3% 
TritonX-100 in PBS for 1 h at room temperature, the sections were incubated at 4 °C overnight with 
mouse primary c-Myc antibody (Invitrogen, 1:50) or rabbit primary antibody against REST (Abcam, 
1:50). On the second day, the sections were washed in PBS three times and then incubated with rabbit 
anti-mouse secondary antibody (1:100, Jackson) at room temperature for 2 h. The sections were then 
washed with PBS three times and placed on microscope slides in Vectashield with DAPI (Vector 
Laboratories). Staining was visualized using a confocal fluorescent microscope (LSM700, Zeiss).   
Single-cell RT-PCR. DRGs were extracted and dissociated using a collagenase-dispase method as 
described [13]. After the dissociation neurons were aspirated (under a microscope) into a patch pipette 
using a conventional patch-clamp setup with negatively pressurised pipette holder. The electrode tip 
was then quickly broken into a 0.2 ml PCR tube containing 0.7 µl of oligo-dT (50 mM), 1 µl of dNTP 
mixture (10 mM), 0.5µl of  MgCl2 (25mM), 0.7 µl of RNaseOUT™ (40 U/µL), 1.4µl of DEPC-treated 
water; the mixture was heated to 65°C for 5 min and then placed on ice for 1 min. Single-strand cDNA 
was synthesized from the cellular mRNA by adding 0.5 µl of RT buffer, 1.5µl of MgCl2 (25mM), 1µl 
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of DTT (1M), 0.5 µl of RNaseOUT™ (40 U/µl) and 1 µl of SuperScript® III RT (200 U/µL) and then 
incubating the mixture at 55°C for 50 min followed by 85°C for 5 min. Synthesis of single-cell cDNA 
was performed using a C1000 Touch thermal cycler-CFX96 Real-time PCR (California, USA). First 
strand synthesis was executed at 95 °C (1 min) followed by 40 cycles (95 °C for 50 s, 60 °C for 50 s, 
72 °C for 55 s) and a final 10 min elongation at 72 °C by adding the specific “outer” primer pairs 
(Suppl. Table 1, available at http://links.lww.com/PAIN/A830) into each PCR tube (final volume 60 
l). Then, 2.5 l of the product of the first PCR was used in the second amplification round by using 
specific “inner” primers (final volume 25 l; Suppl. Table 1, available at 
http://links.lww.com/PAIN/A830). The second amplification round consisted of heating the samples to 
95 °C (1 min) followed by 40 cycles (95 °C for 50 s, 60 °C for 50 sec, 72 °C for 55 s) and 10 min 
elongation at 72 °C. The products of the second PCR were analysed in 2% agarose gels and stained 
with ethidium bromide. SuperScript® III First-Strand Synthesis System Kit and GoTaq Green Master 
Mix were obtained from Takara-Clontech (Invitrogen, USA) and Promega (Madison, USA), 
respectively. 
Statistics. All data are given as mean ± SEM. Differences between groups were assessed by two-
way repeated measures ANOVA with Tukey post-test. Differences were considered significant at p ≤ 
0.05. Single-cell RT-PCR data (detection incidence) were analysed using Fisher’s exact test. Statistical 
analyses were performed using OriginPro 9.1 (Originlab Corporation). *,**,*** indicate significant 
difference from the appropriate control with p ≤ 0.05, p ≤ 0.01 or p ≤ 0.001. 
 
Results 
Overexpression of REST in peripheral afferent fibers induces sustained hyperalgesia. We first 
tested if overexpression of REST in mouse dorsal root ganglion (DRG) neurons is sufficient to generate 
hyperalgesia in mice. To this end we designed adenoassociated virions coding for Myc-tagged REST 
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(AAV2/9-REST). In accord with our previous data showing that overexpression of REST in DRG 
neurons makes them overexcitable [25], unilateral injection of AAV2/9-REST into the DRG of control 
mice (see Methods) resulted in the development of prominent mechanical (Fig.1A) and thermal (Fig. 
1B) hyperalgesia in vivo. The mechanical hyperalgesia was the most pronounced with withdrawal 
threshold (von Frey test, see Methods) changing from 0.84±0.07 g before the injection to 0.20±0.05 g 
at 28 days after the injection (n=10; p≤0.05). Thermal withdrawal latency (Hargreaves test, see 
Methods) changed from 13.7±0.3 s before the injection to 6.5±0.3 s at 28 days after (n=10; p≤0.05). 
Injection of empty AAV2/9 virions produced no effect in either of the tests (Fig. 1A, B). There was 
about two-week delay in the onset of hyperalgesia, likely to be due to the time required for the in vivo 
viral transduction to take place [45]. Mice injected with AAV2/9-REST displayed visible change of 
gait (Suppl. Movie 1, available at http://links.lww.com/PAIN/A826), likely to be a consequence of the 
protective behaviour towards the hyperalgesic paw. Control mice injected with empty virions did not 
demonstrate any noticeable change in gait (Suppl. Movie 2, available at 
http://links.lww.com/PAIN/A827). At 28 days after the viral injection animals were sacrificed and L4 
DRGs were analysed for the presence of exogenous REST using anti-Myc antibody. No specific 
antibody binding was detected in DRGs of mice injected with saline or an empty AAV2/9, whereas 
multiple DRG cell bodies from the AAV2/9-REST injected animals displayed fluorescent staining 
indicative of the exogenous expression of the Myc-tagged REST (Fig. 1C). Quantification of these data 
revealed that approximately 25% of DRG neurons in the ipsilateral L4 DRG of the AAV2/9-REST-
injected mice were Myc-positive (Suppl. Fig. 1, available at http://links.lww.com/PAIN/A830). It must 
be noted that nuclear DAPI staining seen in Fig. 1C identifies all cells in the ganglia (including 
abundant satellite glia and other cell types), not only neurons; neurons were identified by their shape 
during confocal imaging. No fluorescence was detected in the corresponding sections of the spinal cord 
(Fig. 1C, second row from the top), confirming the accuracy of the viral gene delivery. These 
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experiments provide clear evidence that increase of REST expression in DRG neurons is in itself 
sufficient to produce chronic-pain-like phenotype in mice. 
Sensory neuron specific, inducible knockout of Rest prevents development of chronic pain after 
peripheral nerve injury or inflammation. We next thought to test how deletion of Rest specific to 
sensory neurons might affect the development of chronic pain. We crossed the floxed Rest mice [34] 
with the mice expressing tamoxifen-inducible CreER-T2 recombinase under control of advillin 
promoter [20] (advillin is expressed almost exclusively in peripheral sensory neurones [17]). The 
resultant RestloxP/loxP/AvCreER-T2 line (Fig. 2A) allows for Rest to be knocked down in adult animals 
and in sensory neurons specifically. Excision of Rest in DRG neurons by tamoxifen (2 mg; 4 or 5 daily 
i.p. injections) was confirmed by PCR (Fig. 2B). We also confirmed that non-specific knockout of Rest 
was not detectable in the brain or muscle tissue samples (Fig. 2C); trigeminal sensory ganglia were 
used for genotyping in this case to spare DRGs for other experiments. We next set out to test how 
conditional deletion of Rest would affect development of chronic pain in neuropathic or chronic 
inflammation pain models; the schedule of a typical experiment is given in Fig. 2D. 
First we knocked out Rest before inducing chronic inflammation using a hind paw injection of a 
Complete Freund’s adjuvant (CFA) [19].  Consistent with the previous reports [14; 19], CFA induced 
prominent hyperalgesia to mechanical, hot and cold stimuli (Fig. 3A-F) on the ipsilateral, but not on the 
contralateral to CFA injection side in the tamoxifen-injected RestloxP/loxP/WT mice lacking the Cre 
(control). The hyperalgesia persisted for at least two weeks of observation. Strikingly, tamoxifen-
injected RestloxP/loxP/AvCreER-T2 mice displayed complete lack of hyperalgesia to either type of 
stimulation (Fig. 3A-F). These results suggest that REST is instrumental in the establishment of 
chronic inflammatory pain state. Of note is the fact that CFA-induced paw edema was visually not 
different between the tamoxifen-injected RestloxP/loxP/WT and RestloxP/loxP/AvCreER-T2 mice (Suppl. 
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Fig. 2, available at http://links.lww.com/PAIN/A830), suggesting that in the absence of Rest the 
inflammatory response to CFA still occurs. 
Next we tested the effect of Rest deletion in two different models of neuropathic pain (Suppl. Fig. 
3, available at http://links.lww.com/PAIN/A830): spared nerve injury (SNI [8]) and partial sciatic nerve 
ligation (PSNL [32]). As before, we compared the tamoxifen-injected RestloxP/loxP/WT mice lacking the 
Cre (control) with the tamoxifen-injected RestloxP/loxP/AvCreER-T2 mice. As in the case with the CFA 
injection, SNI induced prominent mechanical hyperalgesia, which persisted for the entire period of 
observation (two weeks after surgery in this case) in the ipsilateral but not the contralateral side of the 
control mice. However, the hyperalgesia was completely absent in the RestloxP/loxP/AvCreER-T2 mice 
(Fig. 4A, B). Control mice with SNI displayed protective behaviour towards the injured paw and 
changed gait (Suppl. Movie 3, available at http://links.lww.com/PAIN/A828) but this behaviour was 
not evident in the RestloxP/loxP/AvCreER-T2 mice with the SNI injury (Suppl. Movie 4, available at 
http://links.lww.com/PAIN/A829).  
In the next experiment we tested if we can offset Rest deletion in RestloxP/loxP/AvCreER-T2 mice 
with viral overexpression and if such a manoeuvre would reinstate the development of neuropathic 
hyperalgesia. For this we designed AAV2/9-DIO-REST virions; the use of double-floxed inverse open 
reading frame (DIO) approach. This design restricted the expression of REST to cells expressing Cre 
recombinase [33]. The experiment had the following rationale: after the tamoxifen injection the DRG 
neurons in RestloxP/loxP/AvCreER-T2 mice will start expressing Cre; this will cause REST deletion but 
on the other hands, this would also make these neurons specifically susceptible to infection by the 
AAV2/9-DIO-REST virions. After the injection of tamoxifen, RestloxP/loxP/WT (control) and 
RestloxP/loxP/AvCreER-T2 mice were subjected to SNI injury and 6 days later animals were DRG-
injected with the AAV2/9-DIO-empty or AAV2/9-DIO-REST virions, respectively (Fig. 4C). 
RestloxP/loxP/WT mice developed obvious mechanical hyperalgesia immediately after SNI. Consistent 
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with earlier experiments (Fig. 4A), RestloxP/loxP/AvCreER-T2 mice did not develop noticeable 
hyperalgesia after the SNI, however AAV2/9-DIO-REST injection resulted in a complete recovery of 
the hyperalgesic phenotype (Fig. 4C). Again, there was a delay in the onset of hyperalgesia, but two 
weeks after the viral REST delivery, the RestloxP/loxP/AvCreER-T2 mice with SNI became as 
hyperalgesic as the control (AAV2/9-DIO-empty virus-injected RestloxP/loxP/WT) animals. This 
experiment further supported the hypothesis that rising levels of REST in sensory neurons specifically 
is necessary for the development of neuropathic pain. 
We also tested the expression of REST in DRG neurons following SNI. Consistent with previous 
reports [30; 38; 42], REST immunofluorescence was barely detectable in the DRG of control animals 
(RestloxP/loxP/WT; Fig. 4D, upper panel). However, 2 weeks after SNI many DRG neurons were strongly 
labelled with anti-REST antibody (Fig. 4D, lower panel). Size distribution of REST-positive neurons in 
SNI animals was broadly consistent with the general size distribution of neurons in the same DRG (Fig. 
4E) and this, in turn, was consistent with previous literature [22]. Hence, it is likely that REST up-
regulation induced by injury affects all types of neurons in DRG. 
Qualitatively similar results were obtained with the PSNL injury model. Consistent with previous 
reports, PSNL injury resulted in a prominent mechanical hyperalgesia on the injured (ipsilateral) side, 
as well as a noticeable ‘mirror’ mechanical hyperalgesia in the contralateral paw [30; 32] in the control 
mice (tamoxifen-injected RestloxP/loxP/WT; Fig. 5A, B). Hyperalgesia was absent in the tamoxifen-
injected RestloxP/loxP/AvCreER-T2 mice (on either the ipsi- or contralateral paws; Fig. 5A, B). This 
striking difference was maintained for the entire observation period (21 days after injury in this case; 
Fig. 5A, B). In the next experiment we inverted the order of Rest deletion and the neuropathic injury: 
we performed PSNL, allowed the development of measurable hyperalgesia for one week (Fig. 5C), and 
then applied tamoxifen (daily injections on days 7th-11th after the PSNL surgery; see Methods). 
Mechanical sensitivity was then tested again at days 14 and 21 after the surgery. Tamoxifen injection 
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did not produce any effect in control mice (that is, the PSNL-induced hyperalgesia persisted without a 
change in these animals). Knockout of Rest, in RestloxP/loxP/AvCreER-T2 mice with already developed 
PSNL-induced mechanical hyperalgesia resulted in a significant alleviation of hyperalgesia by 2-9 days 
after the final injection of tamoxifen, though withdrawal threshold did not return to pre-surgery levels 
completely during this period (Fig. 5C). These data suggest that PSNL induced hyperalgesia can be at 
least partially reversed by removal of REST. In some experiments shown in Fig. 5A-C 
RestloxP/loxP/AvCreER-T2 mice displayed somewhat lowered baseline withdrawal thresholds; the 
difference did not reach significance with the statistical test used.  
Of note, in the absence of tamoxifen, RestloxP/loxP/AdvCreER-T2 mice had normal mechanical 
threshold sensitivity and develop hyperalgesia following nerve injury (PSNL) similarly to the WT 
littermates (Suppl. Fig. 4, available at http://links.lww.com/PAIN/A830). Taken together, the results 
presented in Fig. 3-5 clearly indicate that i) sensory neuron specific Rest knock-out prevents 
development of hyperalgesia in three different chronic pain models; ii) neuropathic hyperalgesia can be 
rescued in nerve-injured animals by overexpressing REST in otherwise Rest-deficient sensory 
afferents; iii) under conditions where the nerve-injury-induced hyperalgesia is allowed to develop, 
deletion of Rest produces an anti-algesic effect. 
Upregulation of REST following peripheral nerve injury has been shown to correlate with the 
downregulation of some of its target genes in DRG, including Kcnd3 [39], Kcnq2 [30], Scn10a [38] 
and Oprm1 [38; 44]; these genes are coding for Kv4.3, Kv7.2, Nav1.8 ion channels and µ-opioid 
receptors, respectively. Thus, we used single-cell RT-PCR (see Methods) to test the following: i) if we 
can detect upregulation of REST and reduction in the expression of its targets following nerve injury 
(SNI in this case) on a single cell level; ii) if genetic deletion of Rest could prevent injury-associated 
changes in the expression of REST targets.  
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Two weeks after the induction of SNI DRGs were dissociated and single DRG neurons collected 
for analysis immediately (see Methods). For each gene we quantified the incidence of detection 
(percentage of positive DRG neurons from the total cells tested); these data are presented in Fig. 6 and 
Suppl. Table 2 (available at http://links.lww.com/PAIN/A830). In control mice (tamoxifen-injected 
RestloxP/loxP/WT) following SNI there was a significant increase in Rest-positive neurons (from 19% to 
53%; p≤0.001), accompanied by the significant decrease in the incidence of Kcnq2 (from 58% to 21%; 
p≤0.001) and Kcnd3 (from 61% to 33%; p≤0.001). Incidence of neurons expressing Oprm1 and Scn10a 
was also lower (from 41% to 27%; p=0.07 and from 23% to 16%; p=0.3) but this difference did not 
reach statistical significance (Fig. 6; Suppl. Table 2, available at http://links.lww.com/PAIN/A830). 
The tamoxifen-injected RestloxP/loxP/AvCreER-T2 mice differed from the control in two aspects: i) Rest 
was undetectable in the majority of the cells even after the SNI injury; ii) there was no significant 
reduction in the incidence of their REST target genes we tested (Fig. 6; Suppl. Table 2, available at 
http://links.lww.com/PAIN/A830). While in some Rest-positive neurons other genes of interest were 
also found (Fig. 6B), it is of note that in the majority of ‘de novo’ Rest-positive neurons in the 
tamoxifen-injected RestloxP/loxP/WT mice after SNI the REST target genes tested were not found. Taken 
together these data support our hypothesis that knocking down Rest prevents nerve injury induced 
remodelling of sensory neurons. 
It has to be noted that AAV2/9 injections, CFA and SNI experiments were performed in the Hebei 
Medical University while PSNL experiments were performed at the University of Leeds. Mechanical 
sensitivity was assessed using slightly different methods (mechanical withdrawal threshold 
measurement was used at the Hebei Medical University and the 50% threshold method was used at the 
University of Leeds), which gave somewhat different absolute values (but consistent with the reported 
range [9]). Nevertheless, the outcome of these tests obtained in two laboratories was virtually identical: 
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genetic deletion of Rest abolished the development of chronic pain in neuropathic and chronic 
inflammation pain models.  
 
Discussion  
In this study we demonstrated that transcriptional suppressor REST is necessary and sufficient for 
the development of hyperalgesic state following chronic nerve injury or inflammation. Unilateral 
overexpression of REST in DRG of wild-type mice induced prominent mechanical and thermal 
hyperalgesia in the absence of actual injury or inflammation. In contrast, sensory neuron specific, 
inducible Rest knock-out effectively prevented the development of such hyperalgesic state in three 
different models of chronic pain (CFA, SNI and PSNL). Importantly, hyperalgesia was reinstated in 
nerve-injured mice with Cre-mediated Rest KO by Cre-dependent viral overexpression of REST in 
DRG (Fig. 4C). In addition, genetic deletion of Rest in DRG (Fig. 5C) partially reversed injury-induced 
hyperalgesia. Sensory neuron specific Rest knockout also prevented injury-induced downregulation of 
REST target genes in DRG neurons, as tested with single-cell RT-PCR. In this study we did not 
directly measure binding of REST to the Kcnd3, Kcnq2, Scn10a or Oprm1 promoter regions but such 
binding has been demonstrated in early work by us [25] and others [38; 39]. Taken together our data 
identified REST as one of the key transcriptional regulators of peripheral somatosensory neuron 
remodelling leading to chronic pain. 
Of note is the fact that while deletion of Rest before the onset of either of the three chronic pain 
models used in this study virtually abolished the development of hyperalgesia, Rest deletion one week 
after the PNSL surgery produced only partial alleviation of mechanical hyperalgesia (Fig. 5C). The 
reasons for this difference will have to be established but one explanation could be in that the initial 
upregulation of REST, induced during the first week after the nerve injury, could trigger a cascade of 
long-term downstream changes that cannot be promptly and entirely reversed at this time point by the 
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removal of Rest. On the other hands, if Rest is already absent at the onset of the nerve injury, then these 
downstream changes are prevented altogether. Future studies should test if this hypothesis is correct.  
It has to be pointed out that i) not all REST targets downregulated in chronic pain models are anti-
excitatory and ii) not all REST targets are found downregulated in chronic pain models. In regards to 
the first point above, Scn10a, coding for the excitatory voltage gated Na+ channel Nav1.8 has an RE1 
consensus site and was found downregulated in PSNL model [38]. However, downregulation of Nav1.8 
is perhaps not a universal feature of chronic pain conditions and could be compensated by the 
upregulation of Nav1.8 activity [4] and enhanced expression of other voltage-gated Na+ channels (e.g. 
Nav1.3) in DRG, [42]. Regarding the second point, indeed chronic pain associated upregulation of 
genes encoding L- and T-type Ca2+ channels, vasoactin intestinal peptide VIP and some others have 
been reported (reviewed in [40]). These genes have promoter regions that can bind REST and thus 
would be expected to be downregulated. Yet, there are several considerations that need to be taken into 
account: i) different RE1 sites have different REST affinities, thus, the REST-dependent modulation of 
gene expression is concentration-dependent [27]; this may explain different efficacy (and perhaps 
kinetics) of suppression of potentially REST-sensitive genes during the development of a chronic pain 
state. ii) REST could suppress negative regulators of other genes; this, and the action of other 
transcription factors that might enhance these genes, may compensate for any repressive effect of 
REST. Finally, iii) there could be secondary mechanisms altering REST effect on some specific targets. 
In support of the last notion, increased phosphorylation of the methylated DNA binding protein MeCP2 
in dorsal horn neurons in the chronic inflammatory pain model (CFA) has been reported [16]. MeCP2 
facilitates recruitment of CoREST complex by REST but phosphorylation inhibits this activity and 
might disrupt REST-mediated repression of those genes which are co-repressed by MeCP2 [40]. It 
seems therefore plausible that even though primary function of REST is transcriptional repression, its 
upregulation in chronic pain may result in global multidirectional changes in expression of numerous 
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genes. Consistent with this idea, recent study reported that inhibition of methyltransferase G9a (which 
is recruited to the repressor machinery orchestrated by REST) normalised the expression of over 600 
genes whose expression was either down- or upregulated following nerve injury [21]. 
Among the epigenetic changes observed within the peripheral afferents in chronic pain states there 
is a general downregulation of expression of the K+ channel gene pool [11; 21; 36]. This ‘negative 
drive’ affects representative subunits of all major K+ channel families that are expressed in peripheral 
somatosensory system [11; 36] and includes tonically active K+ channels responsible for maintaining 
low resting excitability of peripheral afferents, specifically - M-type (Kv7, KCNQ) K+ channels [11; 
12; 30] and two-pore (K2P) K+ channels [23; 37]. The case of M-type channels is perhaps the best 
evidenced, indeed these subthreshold, non-inactivating K+ channels are increasingly recognised as 
being among the most important regulators of resting membrane potential and AP firing threshold in 
nociceptors (reviewed in [12]). Kcnq genes encoding M channel subunits have functional RE1 binding 
sites which are able to recruit REST, leading to the inhibition of transcription of Kcnq2-5 [18; 25]. 
Moreover, overexpression of REST in DRG neurons robustly suppressed M current density and 
increased tonic excitability of these neurons [25]. Kcnq2, Kcnq3 and Kcnq5 are consistently 
downregulated in various chronic pain models (reviewed in [12; 15]) and downregulation Kcnq2 
expression was correlated with the increased expression of REST following PSNL [30]. 
Using ENCODE database we identified a number of K+ channel genes that possess RE1 sites and 
were shown to bind REST within cells (Suppl. Table 3, available at http://links.lww.com/PAIN/A830). 
Most intriguingly, a large number of these genes are expressed in nociceptive DRG neurons and 
virtually all of these RE1-containing K+ channel subunits were shown to be downregulated in DRG 
under induced chronic pain conditions. Thus we hypothesize that i) nerve injury induced upregulation 
of REST is one of the major factors of neuropathic remodelling in DRG, and ii) downregulation of K+ 
channel expression by REST-dependent mechanisms is a key mechanism underlying overexcitable 
AC
CE
PT
ED
8 8 .            
17 
 
phenotype of sensory neurons in chronic pain conditions. Consistent with this hypothesis, neuropathic 
injury-induced downregulation of four K+ channel genes: Kcna4, Kcnd4.2, Kcnq2 and Kcnma1 (coding 
for Kv1.4, Kv4.2, Kv7.2 and Slo1, respectively) was prevented by knockout of G9a [21], an enzyme 
recruited by REST upon its binding to RE1 sites of a REST target genes (reviewed in [27]).  
It has to be acknowledged that at the final stages of preparation of this manuscript another study 
with partially overlapping findings has become available [43]. Using different (non-inducible) mouse 
line with sensory neuron specific Rest knockout Zhang and colleagues have shown alleviation of 
neuropathic hyperalgesia in these animals; there was also a partial recovery of hyperalgesia following 
the siRNA downregulation of REST in DRG. These data independently support our findings. One 
difference between our data and the findings reported in reference [43] is that these authors found that 
knockout of Rest in their model only partially alleviated SNI-induced hyperalgesia; while in our hands 
deletion of Rest resulted in almost complete prevention of hyperalgesia in three different pain models 
(including SNI). While reasons for this discrepancy are yet to be established, one hypothesis that could 
explain the difference is that Zhang and colleagues [43] used non-inducible Rest-cKO, therefore, some 
developmental compensatory mechanisms could have partially offset the effect of Rest deletion in adult 
animals in that study. In the present investigation an inducible and conditional Rest knockout has been 
used and the deletion of Rest was performed immediately before the pain model establishment, 
minimizing the engagement of any long-term compensation mechanisms. 
Importantly, most current approaches to tackle chronic pain aim to reduce the sensation of pain 
without the treatment of underlying pathology. Identification of REST as one of the key factors 
controlling neuropathic remodelling of DRG neurons may lead to identification of new therapeutic 
approaches whereby the very development of ‘painful’ nerve phenotype can be prevented or reversed. 
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Figure Legends 
Figure 1. Overexpression of REST in DRG induce hyperalgesic state in mice. (A, B) Injection 
of AAV2/9 coding for Myc-tagged REST into the DRG of the mice in vivo (1.2x1012 vg/ml; 5 µl) 
produced strong mechanical (A) and thermal (B) hyperalgesia (blue symbols, lines; n=10) as compared 
to saline-injected (black symbols, lines; n=6) or empty virus injected (red symbols, lines; n=8) animals.  
*P < 0.05 (two-way repeated measures ANOVA with Tukey post-hoc test). (C) Immunohistochemical 
analysis of Myc expression in L4 DRG of the mice received AAV2/9-REST (top row) or the 
corresponding segment of the spinal cord (second row from the top), empty AAV2/9 particles (second 
raw from the bottom) or saline (bottom row). Blue staining represents DAPI nuclear labelling, green 
staining represents Myc. Three mice (5-6) sections were analysed in each row.  
Figure 2. Tamoxifen induced Rest Knock-out.  (A) Representation of the modified Restfl allele 
showing the loxP sites flanking exon 2. CreER expression is driven by the advillin promoter and is 
restricted to peripheral sensory neurons. In the presence of tamoxifen, CreER activity is induced 
resulting in the loss of Rest exon 2, abolishing REST expression. (B) PCR genotyping of DNA 
extracted from DRG of vehicle (Con) or Tamoxifen (Tam) treated RestloxP/wt/AvCreER-T2 mice. (C) 
PCR genotyping of DNA extracted from trigeminal sensory ganglia (TG), brain, and muscle of 
tamoxifen- (+) or vehicle-treated RestloxP/loxP/AvCreER-T2 mice. Panels (B) and (C) are representative 
of three independent experiments. (D) Schematic of experiments in which tamoxifen-induced Rest 
deletion was performed prior to establishment of chronic pain model; timing of behavioural tests (von 
Frey, Hargreaves or cold plate tests, see Methods) is indicated in blue. 
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Figure 3. Deletion of Rest prevents development of chronic inflammatory hyperalgesia. 
Injection of tamoxifen (at times indicated by red arrows) prevented the development of mechanical (A) 
and thermal (B) hyperalgesia in RestloxP/loxP/AvCreER-T2 (red symbols, lines; n=6) but not in 
RestloxP/loxP/WT (black symbols, lines; n=6) mice which received a hind-paw injection of the Complete 
Freund’s Adjuvant (CFA, 20 µl) at the time indicated by black arrow. Measurements were performed 
on the ipsilateral paw. (C, D) show experiments similar to these shown in (A) and (B), but performed 
on the contralateral paw. *P < 0.05 (n=6 for each group in (C) and (D); two-way repeated measures 
ANOVA with Tukey post-hoc test). (E, F) Cold sensitivity measurements (cold plate test, 1oC; see 
Methods), following the same experimental paradigm as in panels (A-D). Latency to first jump/paw 
flinch and number of jumps/flinches within a 120s trial are shown in (E) and (F), respectively. 
RestloxP/loxP/AvCreER-T2: n=5; RestloxP/loxP/WT: n=6.  *P < 0.05 (n=6 two-way repeated measures 
ANOVA with Tukey post-hoc test). 
Figure 4. Deletion of Rest prevents development of hyperalgesia in spared nerve injury model 
of neuropathic pain. (A) Mechanical sensitivity (withdrawal thresholds) in mice measured at specific 
days relative to spared nerve injury (SNI, black arrow; schematically depicted in Suppl. Fig. 3, 
available at http://links.lww.com/PAIN/A830) in RestloxP/loxP/AvCreER-T2 (red symbols, lines; n=6) 
and RestloxP/loxP/WT (Control; black symbols, lines; n=6). Mice were injected with tamoxifen daily over 
a 4 day period prior to injury (red arrows). Measurements were performed on the ipsilateral paw. (B) 
Similar to (A) but measurements were performed on the contralateral paw are shown; n=6 for both 
groups. (C). RestloxP/loxP/AvCreER-T2 (red symbols, lines; n=5) and RestloxP/loxP/WT (Control; black 
symbols, lines; n=5) were injected with tamoxifen (red arrows) with subsequent SNI surgery (black 
arrow). At day 6 after SNI RestloxP/loxP/AvCreER-T2 mice were DRG-injected with AAV2/9-DIO-
REST virions (1.2x1012 vg/ml; 5 µl), while RestloxP/loxP/WT mice were injected with AAV2/9-DIO-
empty virions (1.1x1012 vg/ml; 5 µl) Mechanical withdrawal threshold was measured on the ipsilateral 
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paw at times indicated. *P < 0.05 (two-way repeated measures ANOVA with Tukey post-hoc test). (D) 
Immunohistochemical detection of REST in DRG of RestloxP/loxP/WT mice (without tamoxifen 
injection) in control conditions (top row) or 2 weeks after the SNI (bottom row). (E) Top panel: cell 
size distribution of all neurons within the DRG of RestloxP/loxP/WT mice (without tamoxifen injection) 2 
weeks after the SNI (3 mice, 6 sections; n=133). Bottom panel: cell size distribution of REST positive 
neurons in the same sections (3 mice, 6 sections; n=61). The neuronal diameter was measured to the 
nearest micrometer and is presented as a frequency distribution. In the top panel, all neuronal cell 
bodies with distinguishable nuclei were quantified, in the bottom panel only REST-positive neurons 
were quantified.  
Figure 5. Deletion of Rest prevents development of hyperalgesia in partial sciatic nerve 
ligation model of neuropathic pain. (A, B) Mechanical sensitivity (withdrawal thresholds) in mice 
measured at specific days relative to partial sciatic nerve ligation (PSNL, black arrow; schematically 
depicted in Suppl. Fig. 3, available at http://links.lww.com/PAIN/A830) in RestloxP/loxP/AvCreER-T2 
(red symbols, lines; n=10) and RestloxP/loxP/WT (Control; black symbols, lines; n=8). Mice were injected 
with tamoxifen daily over a 5 day period prior to injury (red arrows). (C) An experiment similar to that 
shown in the panel A, but tamoxifen was injected (at times indicated by red arrows) after the PSNL 
surgery (time of the surgery is indicated by the black arrow; n=10 for both groups). *P < 0.05 (two-way 
repeated measures ANOVA with Tukey post-hoc test). 
Figure 6. Deletion of Rest prevents nerve injury induced downregulation of REST target 
genes. (A) Examples of single-cell RT-PCR detection of Gapdh, Rest, Kcnq2, Scn10a, Oprm1 and 
Kcnd3 in individual DRG neurons dissociated from either the naïve, tamoxifen-injected RestloxP/loxP/WT 
mice (left), or tamoxifen-injected RestloxP/loxP/WT mice two weeks after SNI injury (middle), or 
tamoxifen-injected RestloxP/loxP/AvCreER-T2 mice two weeks after SNI injury (right). (B) Venn 
diagrams depicting incidence of detection of Rest, Kcnq2, Scn10a, Oprm1 and Kcnd3, in DRG neurons 
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dissociated from the three category of mice, as indicated. Also indicated is the degree of overlap 
between the detection of Rest and either of the other gene in a single cell. Asterisks indicate difference 
between groups linked by the line connectors, as tested with Fisher’s exact test. Numbers within each 
pie chart indicate number of positive cells out of total number of cells analysed; data for Rest are the 
same in each column. More detailed quantification is presented in Suppl. Table 2 (available at 
http://links.lww.com/PAIN/A830). 
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